Sanofi Completes Acquisition of Dynavax, Expanding Adult Vaccination Presence.
ByAinvest
Tuesday, Feb 10, 2026 9:02 am ET1min read
DVAX--
SNY--
Sanofi has completed the acquisition of Dynavax, a vaccine company, for $15.50 per share. The deal includes Dynavax's hepatitis B vaccine, HEPLISAV-B, and its candidate vaccine for shingles, Z-1018, as well as other vaccine projects in development. The acquisition expands Sanofi's presence in adult vaccinations and combines Dynavax's vaccines with Sanofi's commercial reach, global scale, and development capabilities.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet